Skip to main content
Clinical Trials/NCT04367662
NCT04367662
Completed
Not Applicable

Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19

University Hospital, Rouen1 site in 1 country99 target enrollmentApril 9, 2020
ConditionsCOVID-19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID-19
Sponsor
University Hospital, Rouen
Enrollment
99
Locations
1
Primary Endpoint
Factor VIII plasma levels in blood
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Coronavirus COVID-19 is an emerging virus also called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Eighty percent of patients are poor or asymptomatic. However, there are major respiratory complications for some patients, requiring intensive care hospitalization and possibly leading to death in 5% of cases. One of the hypotheses put forward is that much of the pathophysiology is due to endothelial dysfunction associated with disseminated intravascular coagulation.

The covid-19 pathology could induce coagulation impairment as observed during sepsis. An increase in D-dimer levels during covid-19 disease is itself associated with excess mortality. While D-dimers are highly sensitive, they are not specific for clotting activity. They may be increased in many other circumstances, particularly in inflammation.

On the other hand, the infection stimulates the release of extracellular vesicles. These vesicles, of multiple cellular origin, are an actor of vascular homeostasis, and participate in the state of hyperactivation of coagulation. They have a major role in the prothrombotic state and the development of coagulopathy associated with sepsis.

The aim of our monocentric prospective study would be to study early and more specific markers of hypercoagulability and markers of routine endothelial dysfunction, as soon as the patient is hospitalized, in order to predict the risk of hospitalization in intensive care.

Registry
clinicaltrials.gov
Start Date
April 9, 2020
End Date
May 14, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital, Rouen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Any adult patient admitted to Rouen University Hospital for documented SARS-Cov-2 infection (PCR Test or CT scan)
  • Patient who accept to participate to research after reading the information note
  • Patient affiliated with Social Security

Exclusion Criteria

  • Patient under protective guardianship or curatorship

Outcomes

Primary Outcomes

Factor VIII plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Thrombin generation test plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Clinical worsening (yes/no) of the patient during hospitalization

Time Frame: in the 15 days from admission

D-DIMERS plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Antithrombin plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Prothrombin Fragment 2 plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Cross-linked platelets plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Willebrand Factor plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Fibrin monomers plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Prothrombin Fragment 1 plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Microvesicles of platelet plasma levels in blood

Time Frame: 1 hour after admission

Biological analysis using initial blood sampling

Study Sites (1)

Loading locations...

Similar Trials